1. Home
  2. DDL vs TECX Comparison

DDL vs TECX Comparison

Compare DDL & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DDL

Dingdong (Cayman) Limited (each two representing three)

N/A

Current Price

$2.70

Market Cap

546.3M

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$28.74

Market Cap

554.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DDL
TECX
Founded
2014
2019
Country
China
United States
Employees
N/A
60
Industry
Catalog/Specialty Distribution
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
546.3M
554.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DDL
TECX
Price
$2.70
$28.74
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$75.20
AVG Volume (30 Days)
436.4K
162.6K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.06
N/A
Revenue Next Year
$14.86
N/A
P/E Ratio
$16.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.65
$14.39
52 Week High
$3.41
$35.99

Technical Indicators

Market Signals
Indicator
DDL
TECX
Relative Strength Index (RSI) 55.05 46.78
Support Level $2.58 $28.31
Resistance Level $2.78 $31.88
Average True Range (ATR) 0.06 1.32
MACD 0.02 -0.34
Stochastic Oscillator 72.09 13.70

Price Performance

Historical Comparison
DDL
TECX

About DDL Dingdong (Cayman) Limited (each two representing three)

Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: